A phase I/IIa double blind single institute trial of low dose sirolimus for Pendred syndrome/DFNB4-Reference-Cited by-同舟云学术

A phase I/IIa double blind single institute trial of low dose sirolimus for Pendred syndrome/DFNB4

Published:2020-05 Issue:19 Volume:99 Page:e19763
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:Medicine

Author:

Fujioka Masato,Akiyama Takumi,Hosoya Makoto,Kikuchi Kayoko,Fujiki Yuto,Saito Yasuko,Yoshihama Keisuke,Ozawa Hiroyuki,Tsukada Keita,Nishio Shin-ya,Usami Shin-ichi,Matsunaga Tatsuo,Hasegawa Tomonobu,Sato Yasunori,Ogawa Kaoru

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference10 articles.

1. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS)

2. Targeted disruption of mouse Pds provides insight about the inner-ear defects encountered in Pendred syndrome

3. Differences in the Pathogenicity of the p.H723R Mutation of the Common Deafness-Associated SLC26A4 Gene in Humans and Mice

4. Overlapping expression of anion exchangers in the cochlea of a non-human primate suggests functional compensation

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The occurrence and development of induced pluripotent stem cells;Frontiers in Genetics;2024-04-18

2. Chloride/Multiple Anion Exchanger SLC26A Family: Systemic Roles of SLC26A4 in Various Organs;International Journal of Molecular Sciences;2024-04-10

3. Genetic Testing for Hearing Loss and Social Implementation;AUDIOLOGY JAPAN;2024-02-28

4. Autosomal Recessive Non-Syndromic Deafness: Is AAV Gene Therapy a Real Chance?;Audiology Research;2024-02-22

5. Application of Human Stem Cells to Model Genetic Sensorineural Hearing Loss and Meniere Disease;Cells;2023-03-23